Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Journal of Personalized Medicine|January 27, 2017
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewMiranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea L JorgensenJournal of Personalized Medicine|December 7, 2017
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample SizeMiranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-DonaPlos One|February 25, 2016
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewMiranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-DonaJournal of Managed Care & Specialty Pharmacy|November 30, 2020
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"Sarika Ogale, Clarissa Emy Higuchi Zerbini, Miranta Antoniou, et al.Journal of Comparative Effectiveness Research|July 11, 2020
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancerPaula Chu, Miranta Antoniou, Mohit K Bhutani, et al.Pageof 1